Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Illumina Inc. (NASDAQ:ILMN)

Analysis of Profitability Ratios
Quarterly Data

Beginner level

Profitability ratios measure the company’s ability to generate profitable sales from its resources (assets).

Profitability Ratios (Summary)

Illumina Inc., profitability ratios (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Jan 1, 2017 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016 Jan 3, 2016 Sep 27, 2015 Jun 28, 2015 Mar 29, 2015
Return on Sales
Gross profit margin 69.02% 70.34% 70.36% 69.63% 69.24% 68.84% 69.06% 69.01% 69.44% 68.85% 67.98% 66.35% 65.68% 66.26% 67.53% 69.48% 69.91% 69.96% 69.74% 69.80% — — —
Operating profit margin 22.08% 25.69% 27.28% 27.80% 26.42% 24.88% 25.58% 26.49% 28.25% 27.58% 26.29% 22.02% 20.01% 20.06% 21.35% 24.48% 24.80% 24.55% 24.77% 27.61% — — —
Net profit margin 19.70% 20.68% 26.49% 28.28% 28.13% 27.55% 25.05% 24.78% 21.09% 20.88% 19.31% 26.38% 30.14% 30.07% 30.52% 19.29% 18.70% 18.70% 18.40% 20.79% — — —
Return on Investment
Return on equity (ROE) 13.57% 15.19% 20.32% 21.72% 21.92% 21.65% 21.36% 21.98% 19.53% 19.90% 18.85% 26.41% 27.38% 27.54% 29.01% 21.06% 19.79% 21.05% 20.82% 24.97% — — —
Return on assets (ROA) 8.62% 9.56% 12.97% 13.70% 13.73% 13.45% 11.52% 11.87% 10.12% 11.08% 10.23% 13.81% 15.49% 15.39% 16.10% 10.81% 10.49% 10.86% 10.93% 12.52% — — —

Based on: 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-08-07), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-11), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-07-31), 10-Q (filing date: 2019-04-26), 10-K (filing date: 2019-02-12), 10-Q (filing date: 2018-10-24), 10-Q (filing date: 2018-07-31), 10-Q (filing date: 2018-04-25), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-25), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-14), 10-Q (filing date: 2016-11-08), 10-Q (filing date: 2016-08-02), 10-Q (filing date: 2016-05-09), 10-K (filing date: 2016-03-02), 10-Q (filing date: 2015-11-02), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Illumina Inc.’s gross profit margin ratio deteriorated from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020.
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Illumina Inc.’s operating profit margin ratio deteriorated from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020.
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Illumina Inc.’s net profit margin ratio deteriorated from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020.
Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Illumina Inc.’s ROE deteriorated from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020.
ROA A profitability ratio calculated as net income divided by total assets. Illumina Inc.’s ROA deteriorated from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020.

Gross Profit Margin

Illumina Inc., gross profit margin calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Jan 1, 2017 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016 Jan 3, 2016 Sep 27, 2015 Jun 28, 2015 Mar 29, 2015
Selected Financial Data (US$ in millions)
Gross profit 526  428  619  662  648  573  584  590  597  575  538  542  482  434  368  419  426  424  397  410  388  376  375 
Revenue 794  633  859  952  907  838  846  868  853  830  782  778  714  662  598  619  607  600  572  592  550  539  539 
Profitability Ratio
Gross profit margin1 69.02% 70.34% 70.36% 69.63% 69.24% 68.84% 69.06% 69.01% 69.44% 68.85% 67.98% 66.35% 65.68% 66.26% 67.53% 69.48% 69.91% 69.96% 69.74% 69.80% — — —
Benchmarks
Gross Profit Margin, Competitors2
Abbott Laboratories 50.18% 50.97% 52.13% 52.46% 52.39% 52.17% 51.57% 51.32% 50.57% 50.38% 49.39% 47.75% 48.59% 49.21% 51.32% 54.09% 54.17% 53.99% 53.93% 54.19% — — —
AbbVie Inc. 68.74% 73.56% 77.43% 77.64% 77.32% 77.41% 77.07% 76.44% 75.22% 74.93% 75.18% 75.05% 76.85% 76.78% 76.81% 77.25% 77.21% 78.12% 79.28% 80.31% — — —
Amgen Inc. 75.55% 77.15% 78.90% 80.38% 81.19% 81.23% 81.26% 81.80% 81.61% 81.78% 81.69% 81.33% 81.37% 81.26% 81.05% 80.99% 80.68% 80.64% 80.23% 79.82% — — —
Biogen Inc. 87.65% 87.97% 87.47% 86.40% 85.97% 85.59% 85.72% 86.50% 86.12% 86.43% 86.57% 86.72% 87.34% 86.80% 86.56% 87.08% 87.46% 88.21% 88.65% 88.48% — — —
Bristol-Myers Squibb Co. 71.18% 69.47% 68.02% 69.10% 69.90% 70.10% 70.86% 70.98% 70.37% 70.12% 69.62% 70.80% 71.92% 72.78% 74.19% 74.54% 75.56% 75.55% 75.67% 76.39% — — —
Eli Lilly & Co. 78.26% 78.67% 79.22% 78.85% 77.78% 76.67% 74.96% 73.81% 73.39% 72.92% 72.95% 73.46% 73.69% 73.89% 73.78% 73.35% 73.23% 73.72% 74.39% 74.76% — — —
Gilead Sciences Inc. 78.72% 78.25% 79.06% 78.86% 79.27% 78.98% 78.02% 77.61% 79.21% 80.31% 81.82% 82.97% 84.51% 84.71% 85.95% 85.77% 86.36% 86.91% 86.69% 87.54% — — —
Johnson & Johnson 65.68% 65.66% 66.15% 66.42% 66.49% 66.67% 66.80% 66.79% 66.36% 65.69% 66.22% 66.84% 68.20% 69.35% 69.88% 69.84% 69.52% 69.58% 69.25% 69.27% — — —
Merck & Co. Inc. 71.23% 70.06% 70.11% 69.87% 70.13% 69.89% 68.94% 68.06% 67.35% 67.81% 68.22% 68.16% 68.09% 67.92% 66.61% 65.10% 63.89% 62.58% 62.07% 62.19% — — —
Pfizer Inc. 79.86% 79.94% 79.94% 80.25% 79.85% 79.91% 79.36% 79.03% 78.58% 78.24% 78.48% 78.61% 78.66% 78.15% 77.28% 76.66% 76.48% 77.71% 79.09% 80.25% — — —
Regeneron Pharmaceuticals Inc. 87.98% 88.21% 89.72% 90.05% 91.14% 92.27% 92.79% 93.53% 93.36% 93.28% 92.95% 93.24% 93.37% 94.16% 94.53% 93.83% 92.90% 91.38% 90.52% 90.43% — — —
Vertex Pharmaceuticals Inc. 88.01% 87.71% 87.24% 86.84% 86.60% 86.56% 86.74% 86.56% 86.88% 87.31% 87.59% 88.95% 89.04% 89.08% 89.76% 87.64% 87.16% 87.72% 87.39% 87.94% — — —
Zoetis Inc. 69.64% 69.73% 69.51% 68.18% 67.38% 66.92% 66.49% 67.19% 68.12% 68.04% 67.31% 66.55% 65.14% 64.91% 65.30% 65.92% 65.32% 64.90% 64.08% 63.53% — — —

Based on: 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-08-07), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-11), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-07-31), 10-Q (filing date: 2019-04-26), 10-K (filing date: 2019-02-12), 10-Q (filing date: 2018-10-24), 10-Q (filing date: 2018-07-31), 10-Q (filing date: 2018-04-25), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-25), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-14), 10-Q (filing date: 2016-11-08), 10-Q (filing date: 2016-08-02), 10-Q (filing date: 2016-05-09), 10-K (filing date: 2016-03-02), 10-Q (filing date: 2015-11-02), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).

1 Q3 2020 Calculation
Gross profit margin = 100 × (Gross profitQ3 2020 + Gross profitQ2 2020 + Gross profitQ1 2020 + Gross profitQ4 2019) ÷ (RevenueQ3 2020 + RevenueQ2 2020 + RevenueQ1 2020 + RevenueQ4 2019)
= 100 × (526 + 428 + 619 + 662) ÷ (794 + 633 + 859 + 952) = 69.02%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Illumina Inc.’s gross profit margin ratio deteriorated from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020.

Operating Profit Margin

Illumina Inc., operating profit margin calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Jan 1, 2017 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016 Jan 3, 2016 Sep 27, 2015 Jun 28, 2015 Mar 29, 2015
Selected Financial Data (US$ in millions)
Income from operations 162  96  189  268  308  205  204  197  241  227  218  230  181  143  52  143  161  162  121  144  141  152  176 
Revenue 794  633  859  952  907  838  846  868  853  830  782  778  714  662  598  619  607  600  572  592  550  539  539 
Profitability Ratio
Operating profit margin1 22.08% 25.69% 27.28% 27.80% 26.42% 24.88% 25.58% 26.49% 28.25% 27.58% 26.29% 22.02% 20.01% 20.06% 21.35% 24.48% 24.80% 24.55% 24.77% 27.61% — — —
Benchmarks
Operating Profit Margin, Competitors2
Abbott Laboratories 13.39% 12.78% 14.18% 14.21% 13.74% 13.27% 12.31% 11.94% 10.45% 10.11% 8.92% 6.30% 7.89% 8.77% 11.03% 15.27% 14.74% 13.95% 13.64% 14.05% — — —
AbbVie Inc. 28.45% 30.17% 39.86% 39.03% 20.04% 21.85% 19.88% 19.49% 32.99% 32.84% 34.03% 33.99% 37.24% 36.74% 36.33% 36.60% 36.21% 35.00% 34.18% 32.97% — — —
Amgen Inc. 38.59% 39.76% 41.89% 43.57% 44.83% 44.05% 44.53% 45.55% 45.82% 46.46% 46.07% 45.76% 46.66% 46.93% 45.68% 44.74% 43.33% 42.46% 41.53% 40.44% — — —
Biogen Inc. 46.68% 50.93% 51.03% 48.98% 47.13% 46.90% 42.40% 43.77% 44.67% 45.58% 46.49% 43.54% 40.25% 38.72% 41.59% 44.99% 47.59% 47.86% 47.11% 45.44% — — —
Bristol-Myers Squibb Co. 9.27% 11.67% 16.30% 22.62% 28.63% 28.59% 23.43% 22.69% 18.64% 15.93% 17.50% 17.39% 19.71% 21.73% 24.06% 23.83% 19.21% 16.34% 11.09% 11.41% — — —
Eli Lilly & Co. 23.55% 24.48% 25.64% 22.29% 20.00% 19.48% 12.50% 15.15% 12.34% 9.11% 14.88% 9.38% 12.43% 14.23% 12.92% 16.30% 14.31% 14.56% 14.27% 13.47% — — —
Gilead Sciences Inc. 11.01% -4.40% 19.89% 19.38% 19.71% 38.44% 37.87% 37.83% 42.81% 46.25% 51.51% 55.04% 58.72% 58.71% 58.46% 58.87% 61.67% 63.83% 66.22% 69.03% — — —
Johnson & Johnson 24.30% 24.64% 25.62% 24.15% 24.15% 22.63% 22.69% 24.27% 22.59% 23.05% 23.63% 24.07% 27.02% 28.55% 28.83% 28.72% 26.37% 25.66% 25.00% 25.05% — — —
Merck & Co. Inc. 26.87% 25.40% 25.49% 24.77% 25.56% 26.73% 24.38% 19.62% 17.84% 12.28% 13.57% 16.28% 9.92% 16.85% 14.45% 13.51% 19.60% 18.10% 18.19% 17.54% — — —
Pfizer Inc. 24.77% 23.75% 25.38% 25.46% 26.30% 27.50% 26.86% 26.10% 26.18% 26.00% 25.86% 25.92% 24.69% 23.57% 22.94% 22.73% 22.96% 24.02% 24.86% 24.20% — — —
Regeneron Pharmaceuticals Inc. 37.43% 34.64% 30.45% 28.10% 29.55% 29.58% 35.41% 37.77% 37.00% 36.89% 36.54% 35.41% 34.22% 32.29% 28.76% 27.38% 25.67% 26.77% 29.26% 30.51% — — —
Vertex Pharmaceuticals Inc. 44.43% 38.67% 34.05% 28.77% 21.38% 25.48% 23.98% 20.84% 22.38% 3.87% -0.77% 4.95% 1.62% 16.16% 14.62% 0.58% -5.02% -8.65% -23.94% -45.23% — — —
Zoetis Inc. 33.87% 33.36% 32.72% 31.42% 31.01% 29.80% 30.05% 31.12% 33.00% 33.86% 33.02% 32.15% 29.43% 28.34% 28.55% 28.48% 26.22% 24.91% 17.35% 15.74% — — —

Based on: 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-08-07), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-11), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-07-31), 10-Q (filing date: 2019-04-26), 10-K (filing date: 2019-02-12), 10-Q (filing date: 2018-10-24), 10-Q (filing date: 2018-07-31), 10-Q (filing date: 2018-04-25), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-25), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-14), 10-Q (filing date: 2016-11-08), 10-Q (filing date: 2016-08-02), 10-Q (filing date: 2016-05-09), 10-K (filing date: 2016-03-02), 10-Q (filing date: 2015-11-02), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).

1 Q3 2020 Calculation
Operating profit margin = 100 × (Income from operationsQ3 2020 + Income from operationsQ2 2020 + Income from operationsQ1 2020 + Income from operationsQ4 2019) ÷ (RevenueQ3 2020 + RevenueQ2 2020 + RevenueQ1 2020 + RevenueQ4 2019)
= 100 × (162 + 96 + 189 + 268) ÷ (794 + 633 + 859 + 952) = 22.08%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Illumina Inc.’s operating profit margin ratio deteriorated from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020.

Net Profit Margin

Illumina Inc., net profit margin calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Jan 1, 2017 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016 Jan 3, 2016 Sep 27, 2015 Jun 28, 2015 Mar 29, 2015
Selected Financial Data (US$ in millions)
Net income attributable to Illumina stockholders 179  47  173  239  234  296  233  210  199  209  208  68  163  128  367  124  129  120  90  104  118  102  137 
Revenue 794  633  859  952  907  838  846  868  853  830  782  778  714  662  598  619  607  600  572  592  550  539  539 
Profitability Ratio
Net profit margin1 19.70% 20.68% 26.49% 28.28% 28.13% 27.55% 25.05% 24.78% 21.09% 20.88% 19.31% 26.38% 30.14% 30.07% 30.52% 19.29% 18.70% 18.70% 18.40% 20.79% — — —
Benchmarks
Net Profit Margin, Competitors2
Abbott Laboratories 10.50% 9.89% 11.15% 11.56% 10.50% 9.36% 8.53% 7.74% 2.91% 3.13% 1.67% 1.74% 8.37% 4.96% 6.74% 6.71% 6.61% 11.08% 12.00% 21.68% — — —
AbbVie Inc. 18.16% 19.20% 24.77% 23.69% 9.90% 12.62% 16.42% 17.36% 23.50% 20.84% 21.55% 18.82% 24.38% 24.77% 24.07% 23.22% 24.08% 23.11% 23.03% 22.50% — — —
Amgen Inc. 30.91% 31.53% 33.64% 35.32% 36.14% 35.57% 35.93% 37.25% 9.96% 10.72% 10.11% 9.08% 37.36% 37.24% 36.12% 35.27% 35.19% 34.48% 33.86% 33.13% — — —
Biogen Inc. 35.63% 40.91% 40.76% 40.96% 37.91% 37.62% 33.79% 32.93% 24.08% 23.06% 23.54% 20.69% 29.44% 28.10% 30.17% 32.34% 34.03% 33.97% 33.79% 32.95% — — —
Bristol-Myers Squibb Co. -0.11% -1.61% 3.08% 13.15% 23.39% 26.00% 22.09% 21.81% 6.50% 1.74% 4.37% 4.85% 20.56% 22.66% 24.22% 22.94% 18.22% 16.29% 9.31% 9.45% — — —
Eli Lilly & Co. 24.01% 24.48% 23.97% 37.27% 35.10% 33.76% 26.12% 13.16% 1.85% -0.60% 4.82% -0.89% 9.90% 11.12% 10.13% 12.90% 11.73% 11.97% 11.49% 12.07% — — —
Gilead Sciences Inc. 5.56% -1.18% 22.17% 24.35% 12.24% 27.14% 26.93% 25.16% 7.27% 9.69% 14.26% 18.03% 42.90% 43.55% 44.11% 45.07% 48.40% 51.16% 53.48% 56.32% — — —
Johnson & Johnson 21.01% 18.86% 20.75% 18.42% 17.32% 20.08% 17.99% 18.75% 1.89% 1.70% 1.58% 1.70% 21.28% 22.52% 22.87% 23.01% 22.27% 21.20% 22.15% 21.99% — — —
Merck & Co. Inc. 24.33% 22.20% 21.10% 21.01% 20.26% 21.10% 19.50% 14.71% 8.02% 3.25% 3.88% 5.97% 7.15% 12.71% 10.88% 9.85% 13.76% 13.01% 11.72% 11.25% — — —
Pfizer Inc. 17.85% 28.80% 31.17% 31.45% 30.57% 23.58% 21.31% 20.79% 44.63% 42.35% 41.29% 40.55% 18.69% 15.90% 13.88% 13.66% 11.77% 13.47% 14.95% 14.25% — — —
Regeneron Pharmaceuticals Inc. 38.28% 37.30% 28.56% 26.91% 28.13% 28.59% 35.12% 36.42% 28.24% 25.65% 23.54% 20.41% 23.17% 22.05% 19.34% 18.42% 16.85% 15.98% 16.72% 15.50% — — —
Vertex Pharmaceuticals Inc. 44.91% 38.51% 31.35% 28.27% 59.23% 64.13% 66.01% 68.80% 22.87% 15.84% 9.36% 10.59% 8.53% 12.19% 8.78% -6.58% -13.17% -17.66% -30.91% -53.89% — — —
Zoetis Inc. 25.42% 25.50% 25.41% 23.96% 23.76% 22.74% 23.47% 24.52% 20.35% 19.95% 17.97% 16.28% 18.29% 17.50% 17.25% 16.80% 14.10% 13.15% 7.83% 7.11% — — —

Based on: 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-08-07), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-11), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-07-31), 10-Q (filing date: 2019-04-26), 10-K (filing date: 2019-02-12), 10-Q (filing date: 2018-10-24), 10-Q (filing date: 2018-07-31), 10-Q (filing date: 2018-04-25), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-25), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-14), 10-Q (filing date: 2016-11-08), 10-Q (filing date: 2016-08-02), 10-Q (filing date: 2016-05-09), 10-K (filing date: 2016-03-02), 10-Q (filing date: 2015-11-02), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).

1 Q3 2020 Calculation
Net profit margin = 100 × (Net income attributable to Illumina stockholdersQ3 2020 + Net income attributable to Illumina stockholdersQ2 2020 + Net income attributable to Illumina stockholdersQ1 2020 + Net income attributable to Illumina stockholdersQ4 2019) ÷ (RevenueQ3 2020 + RevenueQ2 2020 + RevenueQ1 2020 + RevenueQ4 2019)
= 100 × (179 + 47 + 173 + 239) ÷ (794 + 633 + 859 + 952) = 19.70%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Illumina Inc.’s net profit margin ratio deteriorated from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020.

Return on Equity (ROE)

Illumina Inc., ROE calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Jan 1, 2017 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016 Jan 3, 2016 Sep 27, 2015 Jun 28, 2015 Mar 29, 2015
Selected Financial Data (US$ in millions)
Net income attributable to Illumina stockholders 179  47  173  239  234  296  233  210  199  209  208  68  163  128  367  124  129  120  90  104  118  102  137 
Total Illumina stockholders’ equity 4,700  4,563  4,635  4,613  4,439  4,332  3,985  3,758  3,503  3,257  3,008  2,749  2,855  2,715  2,551  2,197  2,240  2,056  1,991  1,849  1,937  1,794  1,623 
Profitability Ratio
ROE1 13.57% 15.19% 20.32% 21.72% 21.92% 21.65% 21.36% 21.98% 19.53% 19.90% 18.85% 26.41% 27.38% 27.54% 29.01% 21.06% 19.79% 21.05% 20.82% 24.97% — — —
Benchmarks
ROE, Competitors2
Abbott Laboratories 10.78% 10.17% 11.84% 11.86% 10.35% 9.14% 8.48% 7.76% 2.89% 3.03% 1.52% 1.54% 6.57% 3.71% 4.79% 6.82% 6.59% 11.02% 11.81% 20.85% — — —
AbbVie Inc. 48.34% 47.30% — — — — — — — — 179.59% 104.16% 99.42% 110.08% 126.25% 128.41% 93.97% 101.42% 117.94% 130.39% — — —
Amgen Inc. 67.09% 68.48% 80.92% 81.07% 73.83% 73.73% 74.55% 67.15% 15.35% 15.86% 14.21% 7.84% 25.37% 25.77% 25.76% 25.85% 24.65% 24.67% 25.16% 24.71% — — —
Biogen Inc. 47.24% 52.41% 46.85% 44.13% 38.55% 40.87% 33.74% 33.98% 23.15% 24.21% 21.09% 20.13% 27.10% 28.42% 30.31% 30.50% 32.06% 33.48% 35.78% 37.84% — — —
Bristol-Myers Squibb Co. -0.09% -1.15% 1.91% 6.66% 32.04% 38.65% 33.80% 35.07% 10.50% 3.05% 7.18% 8.58% 28.61% 31.20% 33.55% 27.55% 21.56% 19.24% 10.94% 10.97% — — —
Eli Lilly & Co. 115.45% 137.26% 179.72% 319.09% 234.97% 282.08% 252.24% 32.88% 3.44% -1.24% 7.74% -1.76% 14.94% 17.35% 15.58% 19.54% 15.68% 16.85% 15.45% 16.53% — — —
Gilead Sciences Inc. 7.27% -1.43% 22.49% 23.91% 13.07% 26.33% 26.84% 25.51% 6.94% 10.19% 16.82% 22.64% 46.69% 53.86% 61.82% 71.48% 89.38% 105.21% 129.43% 97.70% — — —
Johnson & Johnson 26.35% 24.11% 28.01% 25.42% 24.31% 26.87% 24.90% 25.60% 2.39% 2.18% 1.97% 2.16% 21.39% 22.71% 23.46% 23.49% 21.91% 20.73% 21.40% 21.66% — — —
Merck & Co. Inc. 39.47% 37.91% 38.72% 37.99% 34.70% 33.88% 30.50% 23.30% 10.32% 4.12% 4.69% 6.97% 7.44% 12.89% 10.91% 9.78% 12.55% 11.84% 10.53% 9.94% — — —
Pfizer Inc. 13.31% 22.02% 24.28% 25.77% 24.91% 21.24% 19.52% 17.59% 33.40% 32.31% 29.72% 29.88% 16.14% 14.26% 12.49% 12.12% 9.90% 11.22% 12.09% 10.75% — — —
Regeneron Pharmaceuticals Inc. 31.17% 32.94% 18.79% 19.08% 20.41% 21.21% 25.70% 27.91% 22.85% 22.14% 21.74% 19.51% 21.12% 20.91% 19.79% 20.13% 17.75% 18.23% 19.69% 17.40% — — —
Vertex Pharmaceuticals Inc. 33.08% 27.67% 23.38% 19.34% 40.81% 43.70% 45.63% 47.28% 22.27% 15.46% 9.41% 12.99% 10.93% 15.55% 11.82% -9.69% -21.41% -28.03% -41.73% -59.19% — — —
Zoetis Inc. 46.17% 54.23% 58.52% 55.39% 54.56% 57.03% 59.91% 65.35% 54.96% 56.60% 49.90% 48.81% 47.11% 51.20% 53.14% 55.21% 43.47% 47.09% 32.45% 31.74% — — —

Based on: 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-08-07), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-11), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-07-31), 10-Q (filing date: 2019-04-26), 10-K (filing date: 2019-02-12), 10-Q (filing date: 2018-10-24), 10-Q (filing date: 2018-07-31), 10-Q (filing date: 2018-04-25), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-25), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-14), 10-Q (filing date: 2016-11-08), 10-Q (filing date: 2016-08-02), 10-Q (filing date: 2016-05-09), 10-K (filing date: 2016-03-02), 10-Q (filing date: 2015-11-02), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).

1 Q3 2020 Calculation
ROE = 100 × (Net income attributable to Illumina stockholdersQ3 2020 + Net income attributable to Illumina stockholdersQ2 2020 + Net income attributable to Illumina stockholdersQ1 2020 + Net income attributable to Illumina stockholdersQ4 2019) ÷ Total Illumina stockholders’ equity
= 100 × (179 + 47 + 173 + 239) ÷ 4,700 = 13.57%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Illumina Inc.’s ROE deteriorated from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020.

Return on Assets (ROA)

Illumina Inc., ROA calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Jan 1, 2017 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016 Jan 3, 2016 Sep 27, 2015 Jun 28, 2015 Mar 29, 2015
Selected Financial Data (US$ in millions)
Net income attributable to Illumina stockholders 179  47  173  239  234  296  233  210  199  209  208  68  163  128  367  124  129  120  90  104  118  102  137 
Total assets 7,404  7,248  7,261  7,316  7,089  6,973  7,390  6,959  6,759  5,851  5,542  5,257  5,046  4,858  4,598  4,281  4,228  3,985  3,794  3,688  3,734  3,703  3,499 
Profitability Ratio
ROA1 8.62% 9.56% 12.97% 13.70% 13.73% 13.45% 11.52% 11.87% 10.12% 11.08% 10.23% 13.81% 15.49% 15.39% 16.10% 10.81% 10.49% 10.86% 10.93% 12.52% — — —
Benchmarks
ROA, Competitors2
Abbott Laboratories 4.90% 4.52% 5.36% 5.43% 4.80% 4.23% 3.88% 3.53% 1.24% 1.35% 0.67% 0.63% 2.91% 1.65% 2.12% 2.66% 3.47% 5.72% 6.17% 10.72% — — —
AbbVie Inc. 4.93% 4.65% 9.25% 8.84% 5.48% 7.21% 9.44% 9.58% 11.43% 10.46% 9.20% 7.50% 9.66% 9.87% 9.61% 9.01% 9.12% 8.51% 10.19% 9.70% — — —
Amgen Inc. 11.37% 11.23% 12.45% 13.13% 13.55% 13.40% 12.62% 12.64% 3.27% 3.49% 3.12% 2.48% 10.18% 10.27% 10.14% 9.95% 9.71% 9.85% 9.61% 9.69% — — —
Biogen Inc. 20.38% 23.23% 22.51% 21.62% 19.63% 20.14% 17.65% 17.52% 12.50% 12.39% 11.36% 10.73% 15.11% 15.13% 16.42% 16.19% 17.58% 17.75% 17.87% 18.19% — — —
Bristol-Myers Squibb Co. -0.04% -0.44% 0.74% 2.65% 9.85% 11.24% 14.77% 14.06% 4.24% 1.15% 2.78% 3.00% 12.45% 13.73% 14.68% 13.22% 9.98% 8.74% 4.94% 4.93% — — —
Eli Lilly & Co. 12.68% 13.39% 13.46% 21.17% 20.97% 20.28% 16.46% 7.36% 1.01% -0.34% 2.53% -0.45% 5.17% 5.98% 5.81% 7.05% 6.50% 6.76% 6.68% 6.77% — — —
Gilead Sciences Inc. 2.08% -0.46% 8.31% 8.74% 4.55% 9.42% 9.38% 8.57% 2.47% 3.38% 5.30% 6.58% 17.94% 20.27% 21.90% 23.70% 26.63% 32.71% 36.30% 34.93% — — —
Johnson & Johnson 9.95% 9.59% 11.07% 9.59% 9.10% 10.53% 9.78% 10.00% 0.99% 0.88% 0.79% 0.83% 10.17% 10.69% 11.39% 11.71% 11.36% 10.75% 11.41% 11.55% — — —
Merck & Co. Inc. 12.83% 11.56% 11.95% 11.66% 11.18% 11.15% 10.20% 7.53% 3.93% 1.58% 1.84% 2.72% 3.11% 5.48% 4.50% 4.11% 5.58% 5.32% 4.67% 4.36% — — —
Pfizer Inc. 4.85% 7.96% 9.49% 9.72% 9.51% 8.10% 7.38% 7.00% 14.19% 13.67% 13.21% 12.40% 5.70% 4.94% 4.32% 4.20% 3.51% 4.13% 4.68% 4.16% — — —
Regeneron Pharmaceuticals Inc. 19.62% 20.68% 14.46% 14.29% 15.38% 15.71% 18.88% 20.83% 16.64% 15.99% 15.23% 13.67% 14.69% 14.24% 12.32% 12.84% 11.68% 11.97% 12.56% 11.34% — — —
Vertex Pharmaceuticals Inc. 23.81% 20.37% 16.99% 14.15% 28.53% 31.50% 32.94% 33.57% 14.00% 9.58% 5.72% 7.43% 6.12% 7.91% 6.02% -3.87% -8.38% -10.79% -16.05% -22.26% — — —
Zoetis Inc. 12.12% 12.37% 13.97% 12.99% 12.96% 12.52% 12.75% 13.25% 11.13% 12.96% 11.25% 10.06% 10.09% 11.25% 11.18% 10.73% 8.93% 8.50% 5.07% 4.28% — — —

Based on: 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-08-07), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-11), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-07-31), 10-Q (filing date: 2019-04-26), 10-K (filing date: 2019-02-12), 10-Q (filing date: 2018-10-24), 10-Q (filing date: 2018-07-31), 10-Q (filing date: 2018-04-25), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-25), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-14), 10-Q (filing date: 2016-11-08), 10-Q (filing date: 2016-08-02), 10-Q (filing date: 2016-05-09), 10-K (filing date: 2016-03-02), 10-Q (filing date: 2015-11-02), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).

1 Q3 2020 Calculation
ROA = 100 × (Net income attributable to Illumina stockholdersQ3 2020 + Net income attributable to Illumina stockholdersQ2 2020 + Net income attributable to Illumina stockholdersQ1 2020 + Net income attributable to Illumina stockholdersQ4 2019) ÷ Total assets
= 100 × (179 + 47 + 173 + 239) ÷ 7,404 = 8.62%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROA A profitability ratio calculated as net income divided by total assets. Illumina Inc.’s ROA deteriorated from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020.